• A new patient-reported outcome measure assesses fatigue in patients receiving dialysis.
  • The tool gauges tiredness, energy, and the impact of fatigue on life participation. 

Newswise — Washington, DC (October 22, 2020) — A recent study has validated a new patient-reported outcome measure that assesses fatigue in patients receiving long-term dialysis treatments. The results appear in an upcoming issue of CJASN.

Fatigue, which affects most patients with kidney failure who receive hemodialysis, contributes to poor quality of life and is associated with higher risks of cardiovascular disease, depression, and early death. Unfortunately, fatigue can be difficult to quantify. To address this, Angela Ju, PhD (University of Sydney, in Australia) and her colleagues developed a patient-reported measure of fatigue— called Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Fatigue—and evaluated its potential in 485 adults receiving hemodialysis in the United Kingdom, Australia, and Romania. SONG-HD Fatigue calculates the average fatigue over a period of 1 week, and it gauges tiredness, energy, and the impact of fatigue on life participation.

“Currently, fatigue is assessed in a wide range of different ways using measures that vary in terms of content, length, reliability, and validity. Most are quite lengthy, and it is unclear which measure is the best to use,” said Dr. Ju. “This makes it difficult for researchers to choose how to assess fatigue, and compare effectiveness of interventions evaluated in different studies.” 

The study assessed SONG-HD Fatigue in accordance with the recommended US Food and Drug Administration guidelines for patient-reported outcome measures. The authors concluded that it appears to be a reliable and valid measure to be used in trials involving patients receiving hemodialysis.

“Establishing a core outcome measure for fatigue will allow researchers to do 2 important things: to quickly and accurately assess the impact a new intervention has on fatigue as experienced by patients receiving hemodialysis, and to allow the comparison of interventions across different trials to see which one is superior in terms of its effect on fatigue,” Dr. Ju said. “Patients want to know about fatigue regardless of whether or not the intervention was designed to affect it. The core outcome measure helps to provide this information. Interventions specifically targeting fatigue will require a more comprehensive measure.”

An accompanying editorial notes that “patients on maintenance hemodialysis have been very clear that fatigue is an important problem for them. Investigators such as Ju and colleagues have heard them. Now it is time for all us, clinicians and researchers alike, to do the same.”

A Patient Voice also accompanies the study and provides the perspective of a psychologist who has late-stage chronic kidney disease.

Study co-authors include Angela Ju, Armando Teixeira-Pinto, Allison Tong, Alice C. Smith, Mark Unruh, Sara N Davison, Juan Dapueto, Mary Amanda Dew, Richard Fluck, Michael J. Germain, Sarbjit V. Jassal, Gregorio T. Obrador, Donal O’Donoghue, Andrea K. Viecelli, Giovanni Strippoli, Marinello Ruospo, Delia Timofte, Ankit Sharma, Eric Au, Martin Howell, Daniel S.J. Costa, Samaya Anumudu, Jonathan C. Craig, and Claudia Rutherford.

Disclosures: The authors reported no financial disclosures. 

The article, titled “Validation of a Patient-Reported Outcome Measure for Fatigue in Patients Receiving Hemodialysis: The SONG-HD Fatigue Instrument,” will appear online at http://cjasn.asnjournals.org/ on October 22, 2020, doi: 10.2215/CJN.05880420.

The editorial, titled, “Moving the Science of PROMs Forward: Measuring Fatigue in Hemodialysis Patients,” will appear online at http://cjasn.asnjournals.org/ on October 22, 2020, doi: 10.2215/CJN.14900920.

The Patient Voice editorial, titled, “Fatigue while Undergoing Long-Term Hemodialysis,” will appear online at http://cjasn.asnjournals.org/ on October 22, 2020, doi: 10.2215/CJN.14870920.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.


# # #


Register for reporter access to contact details